Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06603870
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
Secondary Prevention of VTE in Patients with Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Secondary Prevention of Venous Thromboembolism in Patients with Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis STREAM-Line Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STREAM-Line
Brief Summary:
This trial seeks to evaluate a management strategy after the initial 3 months of standard therapeutic anticoagulation for patients with cancer and catheter-related upper extremity deep vein thrombosis DVT
Detailed Description:
The aim of the STREAM-Line Trial is to demonstrate that the STREAM-Line management strategy is safe after the initial 3 months of therapeutic anticoagulation in patients with cancer and catheter-related upper extremity DVT Upon enrollment and during follow-up patients will be managed with a prophylactic dose of apixaban 25 mg orally twice daily as long as either a central venous catheter CVC or active cancer is present STREAM-Line management strategy Apixaban will be stopped at the time of CVC removal and when cancer is in remission Day 9014 and Day 18014 follow-up visit procedures will be done by phone call or in person
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None